Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03098576 · ClinicalTrials.gov registry record
Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute
A clinical trial, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- 52
- Enrollment target
NCT03098576: Completed study, sponsored by Cedars-Sinai Medical Center.
NCT03098576 is a clinical trial that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03098576 has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the usefulness of matching patients to targeted therapy by analyzing a tumor sample taken at diagnosis and testing it against 50 cancer-associated genes. Targeted therapy is a highly personalized, newer approach to cancer treatment that aims to more precisely identify and attack cancer cells, in an effort to do less damage to normal cells.
Primary Outcome
To evaluate the proportion of patients with response to targeted study agent(s) in patients with advanced cancers.
Interventions
- OTHER Matched targeted drug treatment
- OTHER Unmatched standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-03-28 |
| Est. Completion | 2024-03-01 |
What the finished NCT03098576 record still lists
NCT03098576 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Matched targeted drug treatment is the first listed.
NCT03098576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03098576 about?
NCT03098576 is a clinical study titled "Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute". The purpose of this study is to examine the usefulness of matching patients to targeted therapy by analyzing a tumor sample taken at diagnosis and testing it against 50 cancer-associated genes. Targeted therapy is a highly personalized, newer approach to cancer treatment that aims to more precisely ...
What is the current status of trial NCT03098576?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2017-03-28. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT03098576?
The interventions under investigation include: Matched targeted drug treatment (OTHER), Unmatched standard of care (OTHER).
Who is sponsoring clinical trial NCT03098576?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI